MedTrace Logo

Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer

NCT01196455 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2010-09-08

No results posted yet for this study

Summary

This is an open-label, non-comparative efficacy and safety study of Capecitabine and Mitomycin C as first-line treatment in patients with previously untreated metastatic breast cancer.

Conditions

Interventions

DRUG

Capecitabine and Mitomycin C

* Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks * Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Croatian Cooperative Group for Clinical Research in Oncology

    lead OTHER

Principal Investigators

  • Eduard Vrdoljak, MD PhD · Clinical Hospital Split, Center of oncology, Croatia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2011-04-30

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01196455 on ClinicalTrials.gov